CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
Feature|Videos|May 8, 2025
Patient Services: A Marathon, Not A Sprint
Author(s)Rob Truckenmiller, PharmaCord
Rob Truckenmiller, CEO of PharmaCord, talks about the company’s role in patient services, trends he sees shaping patient access to healthcare in the U.S., and a recent patient-centric merger.
Advertisement
In this video, Rob Truckenmiller, CEO of PharmaCord, covers various trends from patient access to specialty medications in the U.S., including trends that are shaping manufacturer strategies. He also defines the difference between enablement and empowerment when it comes to using AI in patient services, and further shares how emerging technologies could influence the future of specialty pharma services.
Key Learning Objectives
- Learn about PharmaCord, its mission, and what distinguishes the organization in a competitive marketplace.
- Understand how patient journeys are evolving in response to market complexity and how manufacturer needs are shifting, and recognize how PharmaCord is building solutions that align with rising expectations.
- Learn about compliant responses regarding PharmaCord's recent press release and strategic growth initiatives, painting a picture of what lies ahead for the organization and the industry at large.
Advertisement
Related to this article
Informa's invitation-only Leadership Summit returns to CPHI Milan Oct. 6 as executives weigh sourcing, medicine security and reshoring pressure.
The EU's pharma reform makes market protection more conditional. Here is how US drugmakers, especially startups, can adapt and use IP to complement it.
The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk taps Anthropic for AI-driven drug discovery, and Sanofi, UCB and Opella join AstraZeneca on a supply chain heat decarbonization program.
DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
Advertisement
Advertisement